Intense investor interest saw 13 million Cybin Inc (Nasdaq: CYBN) shares change hands in intraday trading on Thursday, up from its average of around four…
March 14, 2024
March 14, 2024
SS Innovations Successfully Completes World-First Mitral Valve Replacement with SSi Mantra Surgical Robotic Device
Surgical robotic technology company, SS Innovations International (OTC: SSII) has successfully performed the world’s first mitral valve replacement using the SSi Mantra surgical robotic system…
Commercial stage biopharmaceutical company, TG Therapeutics (Nasdaq: TGTX), has presented data from its ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b…
March 14, 2024
Psyence Group Headed for Phase 2 with Psilocybin Therapeutic for Adjustment Disorder Following Cancer Diagnosis
The therapeutic use of nature-derived psilocybin in mental health and wellbeing continues to rise in popularity. Psyence Group (CSE: PSYG) has announced this week that…
March 13, 2024
Kyverna and Stanford University Collaborate to Investigate Multiple Sclerosis Treatment
Kyverna Therapeutics (Nasdaq: KYTX) will collaborate with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label,…
The FDA supports an accelerated approval pathway for Mesoblast Limited’s (Nasdaq: MESO) rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic…
Biopharmaceutical company, FSD Pharma Inc. (Nasdaq: HUGE) has announced positive results from its Phase 1 study of Lucid-21-302 as a potential treatment to prevent disease…
March 08, 2024
MindMed Soars on FDA Breakthrough Therapy Designation for “Truly Remarkable” Anxiety Candidate, Announces Capital Raise
Mind Medicine Inc. (Nasdaq: MNMD) has been granted FDA Breakthrough Therapy Designation for its generalized anxiety disorder (GAD) treatment candidate, MM120 (lysergide d-tartrate). MindMed also…
Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than one million people in the US alone. Inhibikase Therapeutics (Nasdaq: IKT)…
Shares in Nexalin Technology (Nasdaq: NXL) rose almost 50% in intraday trading on Wednesday after the company announced positive topline results from its clinical study…
March 07, 2024
INmune Bio Demonstrates Significant Improvement in Alzheimer’s Disease Patients with Weekly XPro™ Treatment
Immunology company, INmune Bio, Inc. (Nasdaq: INMB) has demonstrated significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe…
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has received FDA approval of an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of…